Top

Published in:

01-06-2019 | Original Contribution

Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial

Authors: Marc R. Bomhof, Jill A. Parnell, Hena R. Ramay, Pam Crotty, Kevin P. Rioux, Chris S. Probert, Saumya Jayakumar, Maitreyi Raman, Raylene A. Reimer

Published in: European Journal of Nutrition | Issue 4/2019

Abstract

Purpose

In obesity and diabetes the liver is highly susceptible to abnormal uptake and storage of fat. In certain individuals hepatic steatosis predisposes to the development of non-alcoholic steatohepatitis (NASH), a disease marked by hepatic inflammation and fibrosis. Although the precise pathophysiology of NASH is unknown, it is believed that the gut microbiota-liver axis influences the development of this disease. With few treatment strategies available for NASH, exploration of gut microbiota-targeted interventions is warranted. We investigated the therapeutic potential of a prebiotic supplement to improve histological parameters of NASH.

Methods

In a placebo-controlled, randomized pilot trial, 14 individuals with liver-biopsy-confirmed NASH [non-alcoholic fatty liver activity score (NAS) ≥ 5] were randomized to receive oligofructose (8 g/day for 12 weeks followed by 16 g/day for 24 weeks) or isocaloric placebo for 9 months. The primary outcome measure was the change in liver biopsy NAS score and the secondary outcomes included changes in body weight, body composition, glucose tolerance, inflammatory markers, and gut microbiota.

Results

Independent of weight loss, oligofructose improved liver steatosis relative to placebo and improved overall NAS score (P = 0.016). Bifidobacterium was enhanced by oligofructose, whereas bacteria within Clostridium cluster XI and I were reduced with oligofructose (P < 0.05). There were no adverse side effects that deterred individuals from consuming oligofructose for treatment of this disease.

Conclusions

Independent of other lifestyle changes, prebiotic supplementation reduced histologically-confirmed steatosis in patients with NASH. Larger follow-up studies are warranted.

Clinical Trial

This trial was registered at Clinicaltrials.com as NCT03184376.

Available only for authorised users

Rinella ME (2015) Non-alcoholic fatty liver disease. JAMA 313(22):2263–2273. https://doi.org/10.1001/jama.2015.5370 CrossRefPubMed

Yilmaz Y, Younossi ZM (2014) Obesity-associated non-alcoholic fatty liver disease. Clin Liver Dis 18(1):19–31. https://doi.org/10.1016/j.cld.2013.09.018 CrossRefPubMed

Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A (2015) The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One 10(10):e0140908. https://doi.org/10.1371/journal.pone.0140908 CrossRefPubMedPubMedCentral

Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M (2015) Weight loss through lifestyle modification significantly reduces features of non-alcoholic steatohepatitis. Gastroenterology 149(2):367–378.e365. https://doi.org/10.1053/j.gastro.2015.04.005 CrossRefPubMed

Dudekula A, Rachakonda V, Shaik B, Behari J (2014) Weight loss in non-alcoholic fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PLoS One 9(11):e111808. https://doi.org/10.1371/journal.pone.0111808 CrossRefPubMedPubMedCentral

Tilg H, Moschen AR (2010) Evolution of inflammation in non-alcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52(5):1836–1846. https://doi.org/10.1002/hep.24001 CrossRefPubMed

de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira L, Cesar DE, Moreira APB (2018) Influence of gut microbiota on the development and progression of non-alcoholic steatohepatitis. Eur J Nutr 57(3):861–876. https://doi.org/10.1007/s00394-017-1524-x CrossRefPubMed

Moschen AR, Kaser S, Tilg H (2013) Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab 24(11):537–545. https://doi.org/10.1016/j.tem.2013.05.009 CrossRefPubMed

Nieuwdorp M, Gilijamse PW, Pai N, Kaplan LM (2014) Role of the microbiome in energy regulation and metabolism. Gastroenterology 146(6):1525–1533. https://doi.org/10.1053/j.gastro.2014.02.008 CrossRefPubMed

10.

Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, Perlemuter G, Cassard-Doulcier AM, Gerard P (2013) Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62(12):1787–1794. https://doi.org/10.1136/gutjnl-2012-303816 CrossRefPubMed

11.

Brandl K, Schnabl B (2017) Intestinal microbiota and non-alcoholic steatohepatitis. Curr Opin Gastroenterol 33(3):128–133. https://doi.org/10.1097/mog.0000000000000349 CrossRefPubMedPubMedCentral

12.

Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K, Reid G (2017) Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 14(8):491–502. https://doi.org/10.1038/nrgastro.2017.75 CrossRefPubMed

13.

Corradini C, Lantano C, Cavazza A (2013) Innovative analytical tools to characterize prebiotic carbohydrates of functional food interest. Anal Bioanal Chem 405(13):4591–4605. https://doi.org/10.1007/s00216-013-6731-6 CrossRefPubMed

14.

Mokhtari Z, Gibson DL, Hekmatdoost A (2017) Non-alcoholic fatty liver disease, the gut microbiome, and diet. Adv Nutr 8:240–252. https://doi.org/10.3945/an.116.013151 CrossRefPubMedPubMedCentral

15.

Parnell JA, Raman M, Rioux KP, Reimer RA (2012) The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int 32(5):701–711. https://doi.org/10.1111/j.1478-3231.2011.02730.x CrossRefPubMed

16.

Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, Bindels LB, de Vos WM, Gibson GR, Thissen JP, Delzenne NM (2013) Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62(8):1112–1121. https://doi.org/10.1136/gutjnl-2012-303304 CrossRefPubMed

17.

Daubioul CA, Horsmans Y, Lambert P, Danse E, Delzenne NM (2005) Effects of oligofructose on glucose and lipid metabolism in patients with non-alcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr 59(5):723–726. https://doi.org/10.1038/sj.ejcn.1602127 CrossRefPubMed

18.

Kellow NJ, Coughlan MT, Reid CM (2014) Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. Br J Nutr 111(7):1147–1161. https://doi.org/10.1017/S0007114513003607 CrossRefPubMed

19.

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, Non-alcoholic Steatohepatitis Clinical Research N (2005) Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 41(6):1313–1321. https://doi.org/10.1002/hep.20701 CrossRefPubMed

20.

Bruhwyler J, Carreer F, Demanet E, Jacobs H (2009) Digestive tolerance of inulin-type fructans: a double-blind, placebo-controlled, cross-over, dose-ranging, randomized study in healthy volunteers. Int J Food Sci Nutr 60(2):165–175. https://doi.org/10.1080/09637480701625697 CrossRefPubMed

21.

Godin G, Shephard RJ (1985) A simple method to assess exercise behavior in the community. Can J Appl Sport Sci 10(3):141–146PubMed

22.

Fujii H, Kawada N (2012) Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol 47(3):215–225. https://doi.org/10.1007/s00535-012-0527-x CrossRefPubMed

23.

Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21(12):2191–2192CrossRefPubMed

24.

DeFronzo RA, Matsuda M (2010) Reduced time points to calculate the composite index. Diabetes Care 33(7):e93. https://doi.org/10.2337/dc10-0646 CrossRefPubMed

25.

Bomhof MR, Paul HA, Geuking MB, Eller LK, Reimer RA (2016) Improvement in adiposity with oligofructose is modified by antibiotics in obese rats. FASEB J 30(8):2720–2732. https://doi.org/10.1096/fj.201600151R CrossRefPubMed

26.

Nicolucci AC, Hume MP, Martinez I, Mayengbam S, Walter J, Reimer RA (2017) Prebiotics reduce body fat and alter intestinal microbiota in children who are overweight or with obesity. Gastroenterology 153(3):711–722. https://doi.org/10.1053/j.gastro.2017.05.055 CrossRefPubMed

27.

McMurdie PJ, Holmes S (2013) phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 8(4):e61217. https://doi.org/10.1371/journal.pone.0061217 CrossRefPubMedPubMedCentral

28.

Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550. https://doi.org/10.1186/s13059-014-0550-8 CrossRefPubMedPubMedCentral

29.

Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F (2012) Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 57(2):545–553. https://doi.org/10.1007/s10620-011-1887-4 CrossRefPubMed

30.

Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A (2014) Synbiotic supplementation in non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 99(3):535–542. https://doi.org/10.3945/ajcn.113.068890 CrossRefPubMed

31.

Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J (2011) Effect of a probiotic on liver aminotransferases in non-alcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 15(9):1090–1095PubMed

32.

Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R (2011) Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Ped Gastroenterol Nutr 52(6):740–743. https://doi.org/10.1097/MPG.0b013e31821f9b85 CrossRef

33.

Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL (2013) Treatment of non-alcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 12(2):256–262CrossRefPubMed

34.

Bomhof MR, Saha DC, Reid DT, Paul HA, Reimer RA (2014) Combined effects of oligofructose and Bifidobacterium animalis on gut microbiota and glycemia in obese rats. Obesity 22(3):763–771. https://doi.org/10.1002/oby.20632;10.1002/oby.20632 CrossRefPubMed

35.

Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR (2010) Randomized controlled trial testing the effects of weight loss on non-alcoholic steatohepatitis. Hepatology 51(1):121–129. https://doi.org/10.1002/hep.23276 CrossRefPubMed

36.

Morel FB, Dai Q, Ni J, Thomas D, Parnet P, Fanca-Berthon P (2015) Alpha-galacto-oligosaccharides dose-dependently reduce appetite and decrease inflammation in overweight adults. J Nutr 145(9):2052–2059. https://doi.org/10.3945/jn.114.204909 CrossRefPubMed

37.

Parnell JA, Reimer RA (2009) Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 89(6):1751–1759. https://doi.org/10.3945/ajcn.2009.27465 CrossRefPubMed

38.

Daud NM, Ismail NA, Thomas EL, Fitzpatrick JA, Bell JD, Swann JR, Costabile A, Childs CE, Pedersen C, Goldstone AP, Frost GS (2014) The impact of oligofructose on stimulation of gut hormones, appetite regulation and adiposity. Obesity 22(6):1430–1438. https://doi.org/10.1002/oby.20754 CrossRefPubMed

39.

Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, O’Dea K, Desmond PV, Johnson NA, Wilson AM (2013) The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 59(1):138–143. https://doi.org/10.1016/j.jhep.2013.02.012 CrossRefPubMed

40.

Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR (2013) Characterization of gut microbiomes in non-alcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57(2):601–609. https://doi.org/10.1002/hep.26093 CrossRefPubMed

41.

Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP (2013) Intestinal microbiota in patients with non-alcoholic fatty liver disease. Hepatology 58(1):120–127. https://doi.org/10.1002/hep.26319 CrossRefPubMed

42.

Kalliomaki M, Carmen Collado M, Salminen S, Isolauri E (2008) Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 87(3):534–538. https://doi.org/10.1093/ajcn/87.3.534 CrossRefPubMed

43.

Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T, Group LS (2005) Sampling variability of liver biopsy in non-alcoholic fatty liver disease. Gastroenterology 128(7):1898–1906. https://doi.org/10.1053/j.gastro.2005.03.084 CrossRefPubMed

44.

Trabulsi J, Schoeller DA (2001) Evaluation of dietary assessment instruments against doubly labeled water, a biomarker of habitual energy intake. Am J Physiol Endo Metab 281(5):E891–899. https://doi.org/10.1152/ajpendo.2001.281.5.E891 CrossRef

45.

Helmerhorst HJ, Brage S, Warren J, Besson H, Ekelund U (2012) A systematic review of reliability and objective criterion-related validity of physical activity questionnaires. Int J Behav Nutr Phys Act 9:103. https://doi.org/10.1186/1479-5868-9-103 CrossRefPubMedPubMedCentral

46.

Kaczmarek JL, Musaad SM, Holscher HD (2017) Time of day and eating behaviors are associated with the composition and function of the human gastrointestinal microbiota. Am J Clin Nutr 106(5):1220–1231. https://doi.org/10.3945/ajcn.117.156380 CrossRefPubMed

Title: Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial
Authors: Marc R. Bomhof
Jill A. Parnell
Hena R. Ramay
Pam Crotty
Kevin P. Rioux
Chris S. Probert
Saumya Jayakumar
Maitreyi Raman
Raylene A. Reimer
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nutrition / Issue 4/2019
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-018-1721-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Clinical Trial

Please log in to get access to this content

Other articles of this Issue 4/2019

Improved hemodynamic and liver function in portal hypertensive cirrhotic rats after administration of B. pseudocatenulatum CECT 7765

High sodium intake and sodium to potassium ratio may be linked to subsequent increase in vascular damage in adults aged 40 years and older: the Korean multi-rural communities cohort (MRCohort)

The association between the inflammatory potential of diet and risk of developing, and survival following, a diagnosis of ovarian cancer

Total and lean fish intake is positively associated with bone mineral density in older women in the community-based Hordaland Health Study

Correction to: The association between the inflammatory potential of diet and risk of developing, and survival following, a diagnosis of ovarian cancer

Exploring the association between whole blood Omega-3 Index, DHA, EPA, DHA, AA and n-6 DPA, and depression and self-esteem in adolescents of lower general secondary education

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage